Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Harvard Medical School
Headquarters: Boston, MA, United States of America
Website: http://hms.harvard.edu
Year Founded: 1782
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 27, 2025
Emerging Company Profile
Heranova: Detecting endometriosis in the blood like it’s cancer
The Massachusetts-based company launched a microRNA-based liquid biopsy test for endometriosis, with an eye toward disease monitoring and drug development
BioCentury | Feb 26, 2025
Distillery Therapeutics
Inhibition of cancer cell NDUFS4 for antitumor immunity
BioCentury | Feb 20, 2025
Emerging Company Profile
Switch: Precision siRNA knockdown
San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue
BioCentury | Jan 28, 2025
Distillery Therapeutics
Sulfatide-targeting natural killer T cell activation for cardiac arrest-associated neurological injury
BioCentury | Jan 13, 2025
Deals
Quick exit for Idrx shareholders as GSK pays $1B to get GIST asset
Early clinical data show efficacy signals that appear to improve on existing therapies in GI cancer settings
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Dec 16, 2024
Distillery Therapeutics
Targeting a CGRP-RAMP1-nociceptor axis for endometriosis
BioCentury | Dec 5, 2024
Product Development
Stem cell therapy companies take different roads to reproducibility
But they agree that creating a reliable product is necessary for scalability
BioCentury | Nov 4, 2024
Distillery Therapeutics
Inhibiting BTK or CD84 for alcohol-associated hepatitis
Items per page:
1 - 10 of 1627